2023
Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy
Kinslow C, Mercurio A, Kumar P, Rae A, Siegelin M, Grinband J, Taparra K, Upadhyayula P, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Kachnic L, Yu J, Cheng S, Wang T. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncology 2023, 9: 919-927. PMID: 37200021, PMCID: PMC10196932, DOI: 10.1001/jamaoncol.2023.0990.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse to alkylating chemotherapyMGMT promoter methylationMGMT promoter statusOverall survivalAnaplastic gliomasIDH-mutantAlkylating chemotherapyLow-gradePromoter methylationChemotherapy responseAssociated with progression-free survivalCohort studyPromoter statusAssociated with chemotherapy responseMultivariate Cox proportional hazards regression modelsClinical trials of patientsO6-methylguanine-DNA methyltransferaseCox proportional hazards regression modelsIDH wild-typeTrial of patientsIDH wild-type gliomasProportional hazards regression modelsO6-methylguanine-DNAProspective cohort study
2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptake
2020
Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population
Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS. Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. Journal Of The National Cancer Institute 2020, 113: 274-281. PMID: 32785685, PMCID: PMC7936059, DOI: 10.1093/jnci/djaa110.Peer-Reviewed Original ResearchConceptsOpioid-prescribing ratesOpioid prescribingOpioid Prescribing PatternsOpioid-prescribing guidelinesUS opioid epidemicPalliative care providersMultivariable negative binomial regressionNoncancer populationsPrescribing patternsPrescribing ratesSymptom managementCancer survivorsOpioid epidemicDrug claimsCare providersMedicare populationMedicare beneficiariesPrescribingOncologistsNononcologistsNegative binomial regressionOpioidsBinomial regressionPatientsAnnual number
2016
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Wang E, Yu J, Abouassally R, Meropol N, Cooper G, Shah N, Williams S, Gonzalez C, Smaldone M, Kutikov A, Zhu H, Kim S. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology 2016, 95: 88-94. PMID: 27318264, DOI: 10.1016/j.urology.2016.06.010.Peer-Reviewed Original ResearchConceptsHigh-risk prostate cancerWatchful waitingRadiation therapyProstate cancerPrimary treatmentTreatment of high-risk prostate cancerOdds ratioNational Cancer Data BaseMultivariate logistic regression analysisTreatment of patientsLogistic regression analysisRadical prostatectomyPrimary therapyCurative therapyPrimary outcomeCancer communityTherapySignificant racial disparitiesAcademic hospitalPatientsBlack menCancerHospitalStudy periodWhite men